Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, the American Cancer Society projects 1,898,160 new cancer cases and 608,570 cancer deaths in the United States. Solid tumors represent approximately…
Roche's Genentech unit will pay Adaptimmune Therapeutics $150 million upfront and up to $3 billion more in milestones to develop allogeneic and personalized…
Adaptimmune receives FDA accelerated approval of TECELRA (afami-cel), first engineered cell therapy for a solid tumor (not part of Genentech deal).
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
Genentech (a member of the Roche Group) and Adaptimmune entered a strategic collaboration on September 8, 2021 to research, develop and commercialize allogeneic (off-the-shelf) T-cell therapies against up to five shared cancer targets, plus personalized allogeneic T-cell programs. Adaptimmune received $150M upfront and was eligible for up to $150M in additional payments over five years, with total potential value exceeding $3B in development, regulatory and commercial milestones plus royalties. On April 12, 2024 Adaptimmune disclosed that Genentech had terminated the collaboration in its entirety (notice received on/around April 10, 2024; effective 180 days later, ~October 2024) while the allogeneic and personalized programs were still in discovery. Adaptimmune realized only the $150M upfront plus roughly $35M in milestone payments of the >$3B potential, and refocused on its late-stage autologous pipeline — afami-cel (TECELRA) won FDA accelerated approval on August 2, 2024 for synovial sarcoma, though that asset was not part of the Genentech collaboration.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Adaptimmune Therapeutics plc (this deal) | 2021 | $3.3B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2021 deals · Roche Holding AG deals · Oncology deals